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ABSTRACT 
Probiotics are live, selected microbial strains that have a beneficial effect on 
the human body and when introduced into the body, they colonize in the 
digestive tract, especially in the large intestine, exerting a beneficial effect on 
the health of the host. The microbial strains, so that they can be included in the 
probiotics, must be thoroughly tested and meet several conditions. These 
microorganisms multiply in the gastrointestinal tract and are competitive for 
pathogenic microorganisms that cause infection. Probiotic bacteria are found 
in natural yogurts, sour milk, sauerkraut, pickled cucumbers. Many studies 
show a positive correlation between the consumption of probiotics and the risk 
of developing certain cancers. Probiotics are most likely to reduce the risk of 
developing colorectal cancer. 
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INTRODUCTION 
 
 Among the microorganisms of the natural microflora, bacteria with probiotic properties play an 
enormous role. These bacteria have a beneficial effect on the functioning of the human body, both local and 
systemic [1-3]. For a microbial species to be considered as probiotic it must be fully understood. Detailed 
studies of its impact on the human and animal organism last even several years. Clinical procedures, during 
which a given species of a microorganism is classified as probiotic, consist of three phases: strain's safety 
assessment, checking the effectiveness of the strain and verification of the strain's effectiveness on a large 
number of people and comparison of the effects of treatment with standard therapy [2, 4, 5]. 
 Moreover, the qualified strain should meet the following criteria: it must come from the natural healthy 
microflora of the human intestine, it is an absolute or relative anaerobe, it should belong to a specific type and 
species that has been assigned to it using molecular methods, it should be resistant to acidic pH of gastric juice, 
bile salts and digestive enzymes, its positive effect should be scientifically confirmed and must maintain, it 
cannot show pathogenic or toxic properties, its all properties during processing and storage [6-8]. 
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CHARACTERISTICS AND FUNCTION OF PROBIOTICS 
 
 The characteristics of the probiotics are strain-dependent. Positive properties of one microorganism will 
not necessarily occur in another, even closely related one. Probiotics activity may always refer only to one 
tested strain, not to the species, genus or to all lactic bacteria [2, 4, 5]. The composition of the probiotic may 
contain single strains of lactic acid bacteria (Lactobacillus spp., Streptococcus spp.), yeast (Saccharomyces 
spp.) or lactic acid bacteria in combination with yeast strains. Probiotic bacteria are found in fermented foods 
and can also be found in pharmaceutical preparations [9]. 
 
 
Table 1. Classification of probiotics. 
Genus Species 
Lactobacillus spp. acidophilus, brevis, casei, delbrueckii gasseri, fermentum, johnsonii, lactis, 
paracasei, plantarum, reuteri, rhamnosus  
Bifidobacterium spp. adolescentis, animalis, bifidum, breve, infantis, lactis, longum, thermophilum  
Bacillus spp. coagulans 
Streptococcus spp. thermophilus 
Enterococcus spp. faecium 
Saccharomyces spp. cerevisiae 
 
 
 The advantages of probiotics are used in many fields, e.g. they restore the natural intestinal microflora 
after the antibiotic treatment, they are used for the production of functional food and for the preservation of 
food products [10]. 
 To notice the beneficial effect of probiotics on the body, they should be consumed for a long time so that 
the positive microflora persists at a high level. The composition of the intestinal microflora depends mainly on 
the type and composition of the food consumed and the age of the person. Intestinal flora is affected by past 
infections, antibiotic therapy, availability and composition of substrates for microflora growth, interactions with 
the immune system, intestinal pH, bacterial metabolites, intestinal status, as well as place of residence and 
lifestyle [10-12].  
 Bacteria with beneficial effects classified as probiotics are usually heterogeneous gram-positive, 
catalase-negative cocci or rods of the genera Lactobacillus, Lactococcus, Streptococcus, Oenococcus, 
Pediococcus, Leuconostoc, Enterococcus, Bifidobacterium and rare Weissella, Carnobacterium, 
Tetragenococcus, Vagococcus etc. All of them are able to carry out the anaerobic fermentation of saccharides. 
They produce lactic acid at the level of 0.6% to 3.0%, during the fermentation process. 
 They produce L (+) lactic acid or D (-) lactic acid. If they only produce this acid, they are classified as 
homofermentative bacteria. However, when they also produce acetic acid, ethanol, carbon dioxide, succinate 
and formate in addition to lactic acid derivatives, they are heterofermentative bacteria. The natural habitat for 
the occurrence of lactic acid bacteria is: alimentary canal of humans and animals, milk, plants, mucous 
membranes of the oral cavity and reproductive organs [8, 13]. 
 Numerous studies confirm the beneficial effect of probiotics on human health, which became the basis 
for their use both in the prevention and treatment of many diseases [1, 2]. 
 
PROBIOTICS AND COLON CANCER 
 
 Probiotics have a positive effect on intestinal epithelial cells - colonocytes. They provide them with 70% 
of the energy that is needed to regenerate the intestinal wall in the case of pollutants from the environment. The 
most important role is played by bacteria that bind to the adhesive receptors in the gastrointestinal tract using 
64 | Wolek et al.   Probiotics in colon cancer prevention 
 
 MicroMedicine 2018; 6 (2): 62-68 
 
fimbriae. Probiotic bacteria without fimbria must be delivered in larger quantities with food. An important 
feature of probiotics is also multiplication in the large intestine [14]. 
 In the gastrointestinal tract of an adult, microflora constitutes over 1000 different species of 
microorganisms [1, 2]. Among them are lactic bacteria, which play an important role in delaying the process of 
colon cancer formation, most likely affecting metabolic, immune and protective functions. Their amount may 
increase in the large intestine after ingestion of food containing probiotics. Additional beneficial effects 
indicated by probiotics are alleviation of lactose intolerance, increasing the humoral immune response, 
biotransformation of isoflavone phytoestrogen to reduce postmenopausal symptoms, and lowering serum 
cholesterol [15-17]. 
 Probiotics have an inhibitory effect on the process of carcinogenesis. This is influenced by the ability to 
reduce harmful bacteria such as Clostridium, Peptostreptococcus and Staphylococcus. Probiotic bacteria affect 
the inhibition of β-glucoronidase, β-glucosidase and nitroreductase produced by pathogenic bacteria.These are 
pro-carcinogenic faecal enzymes that are responsible for the growth of colon cancer cells. Probiotics also 
destroy carcinogens such as nitrosamines and their precursors, and also act destructively on nitroreductase, 
which is involved in the synthesis of nitrosamines. They positively affect the immune response, increase and 
development of harmful intestinal microflora, are responsible for the production of antimutagenic substances 
and the production of lactic acid, which stimulates apoptosis, inhibits the conversion of bile salts into secondary 
bile salts [18].  
 Some of the bacteriocins produced by probiotic bacteria are cytotoxic for cancer cells comparing to 
healthy cells. Bacteriocins, which are cationic, hydrophobic peptides, bind to a negatively charged cell 
membrane of tumor cells. The cause of this selective binding to the membrane of tumor cells is also due to the 
difference in the fluidity of their membrane and the greater number of microvilli comparing to normal cells. 
The bacteriocins cytotoxicity mechanisms include the induction of apoptosis and depolarization of the cell 
membrane leading to changes in permeability [19, 20]. 
 
 
 
Figure 1. Ways act probiotics. 
65 | Wolek et al.   Probiotics in colon cancer prevention 
 
 MicroMedicine 2018; 6 (2): 62-68 
 
 Colorectal cancer is the second cancer in Poland with the highest mortality [7, 8]. Every year, almost 
16,000 new cases are diagnosed. Cancer risk factors are hereditary and environmental factors. Hereditary 
factors include familial polyposis, hereditary non-arterial colon cancer, Lynch I and II syndromes and 
ulcerative colitis. Environmental factors include pollution, exposure to certain chemicals, consumption of high-
fat low-fiber diets and lack of physical activity [21, 22]. 
 In animal and human studies on the effect of probiotics on factors predisposing to colorectal cancer, 
researchers investigated the increase of enzymes activity that activate carcinogens, increase the amount of 
proto-oncogenic chemicals in the colon, or alter populations of certain types or species of bacteria [23-31]. 
Many studies have shown that factors that can influence the occurrence of colorectal cancer are positively 
affected by the consumption of certain probiotics [23, 25, 26]. However, these studies do not show a causal 
relationship to the development of colorectal cancer and are circumstantial. Studies that directly examine the 
causal relationship are animal studies. In people with colorectal carcinomas a significant disturbance of the 
intestinal microflora is observed, which plays an important role in the pathogenesis of this common disease. 
Early studies have shown that the metabolic activity of intestinal microorganisms leads to the production of 
carcinogens or pro-carcinogens in the large intestine [32]. Under the influence of microflora, the activation of 
procarcinogens delivered to the body with the diet and biliary excreted to the large intestine, carcinogen 
synthesis and enzymatic modification of carcinogenic compounds detoxified in the liver are caused [32]. 
 Animal studies show that only 20% of animals free from the microorganisms have chemically induced 
colon cancer. In animals with microflora, this value was 93%. Cytochrome P450 studies at the molecular level 
have shown that some of the P450s are also active carcinogens. Epidemiological studies show a higher risk of 
colorectal cancer in people with high CYP1A2 activity. The effect on this cancer in humans is mediated by the 
metabolic activation of food-borne heterocyclic amines that occurs via N-oxidation followed by O-acetylation 
with N-acetoxyarolamine formation, which binds to DNA to form carcinogenic adducts from DNA. These steps 
are catalyzed by the hepatic cytochrome CYP1A2 and acetyltransferase-2 (NAT-2) respectively [33]. 
Probiotics such as Bifidobacterium produce metabolites that may affect the function of P450 and cause the 
conversion of azoxymethane to the carcinogenic factor. These tests, along with experiments carried out by 
Reddy et al. suggest that the probiotic can affect the development of colon cancer. They showed in studies that 
stimulated growth of Bifidobacterium in the colon of rats may lead to inhibition of colon cancer, and suggested 
that the effect on the foci and the number of crypts in the large intestine has the effect of Bifidobacterium, 
which inhibit the growth of E. coli bacteria by lowering the pH. Reducing the amount of these microorganisms 
can also affect the modulation of bacterial enzymes, such as beta-glucuronidase, which can transform pro-
carcinogenic factors into cancerogenic ones [23]. 
 Studies on the antimutagenicity of probiotics show that antimutagenic substances can be found in the 
cellular envelope of the bacterial cell wall [35]. During in vitro studies on colon cancer cells isolated from 
mice, Bifidobacterium infantis was found to inhibit the activity of this tumor. 
 These studies suggest that mutagens bind to the cell wall of probiotics and that Bifidobacterium binds to 
the final carcinogen methylazoxymethanol and the mutagen-carcinogen 3-amino-1,4-dimethyl-5H-pyrido [4,3-
b] indole, thus removing it from the faeces, and then minimizing its absorption into the lumen of the intestine 
[24, 35]. 
 The conducted research shows that a significant role in bacterial antimutagenicity may play the stage of 
their growth. In the phase of linear growth, significant antimutagenic activity is achieved, reaching the 
maximum level, which then decreases in the stationary growth phase [36, 37]. 
 Baricault et al. performing an in vitro study of HT-29 colon carcinoma cells to which fermented milk 
was added, concluded that a protective action of probiotics is based on the change of cancer cells differentiation 
process. The milk was prepared to fermentation using single strains of Lactobacillus helveticus, 
Bifidobacterium, L. acidophilus or mixture of Streptococcus thermophilus and L. delbrueckii subsp. bulgaricus. 
On the basis of the research, it was shown that 10-50% of HT-29 cells under the influence of fermented milk 
inhibited their growth. Subsequent studies have shown that the activity of specific markers responsible for the 
differentiation of HT-29 cells such as dipeptidyl peptides has been increased [38].  
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 Singh et al. performing analyzes on male F344 rats, evaluated the effect of Bifidobacterium longumna on 
the development of colorectal cancer. The obtained results showed that the administration of lyophilized                  
B. longum cultures in food products inhibited the incidence of colon cancer and also reduced the tumor volume. 
Bacteria B. longum also inhibited azoxymethane induced cell proliferation by lowering ornithine decarboxylase 
(ODC) activity [34]. Ornithine decarboxylase participates in polyamine biosynthesis, which is responsible for 
the proliferation, differentiation and macromolecular synthesis of cells. The increase in ODC activity correlates 
with the growth of colorectal adenoma, which indicates a hyperproliferative state of the colonic mucosa [39]. In 
the conducted studies, it was also shown that the anti-tumor effect is affected by the reduced expression of ras-
p21 oncoprotein. Activation of ras proto-oncogenes may induce a malignant phenotype in colon cells [40]. The 
malignant potential of ras genes is related to the mutation in codons 12, 13 or 16 [41]. 
 The study suggests that the administration of Lactobacillus rhamnosus and Bifidobacterium animalis ssp. 
lactis Bb12, reduces the risk of colorectal cancer as a result of the reaction with endogenous or exogenous 
carcinogens [42]. Research results of Witkin et al. showed a correlation between the presence of Lactobacillus 
ssp. and Eubacterium aerofaciens strains, and a reduced risk of colon cancer [43]. Moreover, epidemiological 
studies in Finland have shown that high intake of probiotic products resulted in a reduction in the incidence of 
colorectal cancer despite high fat intake [44].  
 
CONCLUSIONS 
 
 Studies that have been published so far do not show clearly that probiotics can prevent colorectal cancer. 
Epidemiological research is contradictory. Some of them show a lower risk of colon cancer in people 
consuming probiotics, but there are also those that did not show a relationship the consumption of fermented 
milk products and the risk of developing disease. Furthermore, not all protective activities of colostoma 
probiotics were confirmed during in vivo tests. Inconsistent data from these studies may be related to the 
complexity of carcinogenesis, experimental design, variability of probiotic strains and changes in cancer stages. 
The onset of cancer related processes in the body occurs many years before the diagnosis, while the 
colonization of the digestive tract by the intestinal microflora is a very dynamic process, changing under the 
influence of pH, differences in the content of nutrients and oxygen. Despite the many different results obtained 
during probiotic studies, further studies are needed to confirm their clinical efficacy. 
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